Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: are we ready for a continued market sell-off?

December 6, 2018 8:24am

Indications: The iShares Nasdaq Biotechnology (IBB -1.36%), the SPDR S&P Biotech ETF (XBI -1.5%), the iShares Russell 2000 (IWM -1.3%), the Health Care Select Sector SPDR ETF (XLV -1.06) are DOWNSLIDING

News: Intellia Therapeutics (NTLA) expands existing cell therapy collaboration with Novartis, to include the ex vivo development of innovative cell therapies using certain ocular stem cells. Biogen (BIIB) exercised its option to obtain from Ionis Pharmaceuticals (IONS) a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1RX), an investigational treatment for amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutations.

Pre-open indications: a sector bounce is needed as I rank 14 OVERSOLD to BUYs; maybe not today; yet it’s coming!

I answer one question, in which company should investors put, keep and commit their money!

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

1 hour 16 min ago
RegMed Investors (RMi) Research Note: Q1/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes

1 hour 17 min ago
RegMed Investors (RMi) Closing Bell: the path forward

10 hours 24 min ago
RegMed Investors’ (RMi) pre-open: buckle up

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.